Can I Take Creatine with Addyi (Flibanserin)?

What Is Addyi (Flibanserin) and How Does It Work?

Flibanserin is a non-hormonal, centrally acting drug approved by the FDA in August 2015 for the treatment of generalized acquired HSDD in premenopausal women. It acts as a serotonin 1A (5-HT1A) receptor agonist and a serotonin 2A (5-HT2A) receptor antagonist, which together shift the balance between inhibitory serotonin signaling and excitatory dopamine and norepinephrine signaling in the prefrontal cortex. The net result is an increase in sexual desire over time rather than an acute, on-demand effect.

FDA Approval and Clinical Evidence

The key trials submitted to the FDA were the BOUQUET program, a series of three phase 3 randomized controlled trials (DAISY, VIOLET, and BEGONIA) enrolling more than 2,400 premenopausal women combined. Across those trials, women taking flibanserin 100 mg nightly reported approximately 0.5 to 1.0 additional satisfying sexual events per month compared with placebo, alongside meaningful reductions in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). The FDA's own review noted that the benefit is modest but statistically and clinically significant for the indicated population [1].

Pharmacokinetics Relevant to Supplement Interactions

Flibanserin is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19. Potent CYP3A4 inhibitors (for example, fluconazole, ketoconazole, or grapefruit juice) can increase flibanserin plasma concentrations 4- to 7-fold, dramatically raising hypotension and syncope risk [2]. Creatine does not inhibit or induce CYP3A4 or CYP2C19 at any dose reported in the literature, so there is no pharmacokinetic basis for a direct drug-supplement interaction.

What Is Creatine and Why Does It Raise Serum Creatinine?

Creatine is one of the most studied sports supplements in existence. More than 500 peer-reviewed trials have examined its safety and efficacy. The compound is synthesized endogenously in the liver and kidneys from the amino acids arginine and glycine, and approximately 95% of the body's total creatine pool resides in skeletal muscle as free creatine or phosphocreatine.

The Creatinine Question

Serum creatinine is the primary clinical proxy for renal function, calculated into the estimated glomerular filtration rate (eGFR) using the CKD-EPI or MDRD formulas. Creatinine is the non-enzymatic breakdown product of creatine and phosphocreatine. When creatine loading raises the muscle creatine pool, the spontaneous degradation rate of that creatine increases proportionally, producing more creatinine that spills into the bloodstream and urine.

A crossover study in healthy male athletes published in the Journal of the International Society of Sports Nutrition found that creatine monohydrate loading (20 g per day for 5 days) raised serum creatinine by a mean of 0.17 mg/dL without any accompanying change in cystatin C, insulin clearance, or 24-hour creatinine clearance, confirming a laboratory artifact rather than true kidney injury [3]. A separate Cochrane-reviewed meta-analysis of 22 clinical trials found no evidence that creatine supplementation harms renal function in healthy individuals or those with mild pre-existing kidney disease [4].

What This Means in Practice

The elevation in serum creatinine is real but reflects increased creatine turnover, not impaired filtration. The problem is that a prescriber who checks serum creatinine as part of routine Addyi monitoring and sees a rise from, say, 0.8 to 1.0 mg/dL may incorrectly interpret that as a reason to reduce the flibanserin dose or discontinue it entirely. Transparent communication between the patient and prescriber prevents that outcome.

Is There a Direct Drug-Supplement Interaction Between Flibanserin and Creatine?

No direct pharmacokinetic or pharmacodynamic interaction exists. The answer matters, and the reasoning is worth reviewing in detail.

Pharmacokinetic Pathway Check

Flibanserin is absorbed in the small intestine, reaches peak plasma concentration (Cmax) in approximately 45 minutes to 1 hour, and has a half-life of about 11 hours [2]. It is a substrate of CYP3A4 and CYP2C19. Creatine, by contrast, is absorbed via the sodium-dependent creatine transporter SLC6A8 in the gut and muscle, requires no hepatic cytochrome P450 metabolism, and is excreted unchanged by the kidneys or converted to creatinine. Because neither molecule travels the same metabolic highway, they cannot slow or accelerate each other's clearance.

Pharmacodynamic Pathway Check

Flibanserin acts on central serotonin and dopamine receptors. Creatine's central effects, if any, are under active investigation in neurological disease models, but there is no published evidence that supplemental creatine alters serotonin 1A receptor density, dopamine transporter expression, or any pharmacodynamic target shared with flibanserin [5]. Two drugs (or a drug and a supplement) produce a pharmacodynamic interaction only when they act on the same receptor, downstream signaling pathway, or physiological endpoint. That condition is not met here.

The Indirect Risk That Does Exist

The meaningful risk is the laboratory interference described above. An uninformed prescriber seeing rising creatinine may also worry about flibanserin's renal excretion. Approximately 44% of a flibanserin dose is excreted in the urine (largely as metabolites), so genuine renal impairment does alter drug exposure. The FDA label states that flibanserin should be used with caution in patients with renal impairment and that no dose adjustment has been formally studied [2]. A falsely elevated creatinine driven by creatine loading could trigger unnecessary caution about a drug that is actually clearing normally.

Renal Safety Monitoring for Women Taking Both

Because the concern is entirely in the lab rather than in the body, a structured monitoring approach resolves it cleanly.

Recommended Monitoring Timeline

The HealthRX clinical team recommends the following stepwise monitoring plan for women taking Addyi who want to add creatine:

1. Before starting creatine: Obtain a baseline comprehensive metabolic panel (CMP) including serum creatinine, blood urea nitrogen (BUN), and a urinalysis. Document the result in your chart and share it with your Addyi prescriber.
2. Creatine loading phase (if used): Standard loading is 20 g per day in four 5 g servings for 5 to 7 days, followed by a maintenance dose of 3 to 5 g per day. Many women skip loading and start directly at 3 to 5 g per day, which produces the same creatine saturation over approximately 28 days with smaller creatinine spikes.
3. At 4 to 6 weeks: Recheck serum creatinine and BUN. Compare to baseline. An increase of up to 0.2 mg/dL with a stable BUN-to-creatinine ratio and no other signs of kidney dysfunction (no proteinuria, no hematuria, no change in urine output) is consistent with creatine-related creatinine elevation and does not require flibanserin dose adjustment.
4. If creatinine rises more than 0.3 mg/dL: Add cystatin C to the panel. Cystatin C is not affected by muscle mass or creatine turnover, so it provides a cleaner signal of actual glomerular filtration. If cystatin C remains stable, the creatinine rise is almost certainly a creatine artifact.
5. Ongoing: Annual CMP while taking both supplements is reasonable for otherwise healthy premenopausal women with no pre-existing renal disease.

Who Should Be More Cautious

Women with a history of chronic kidney disease (CKD stages 2-5), a solitary kidney, recurrent kidney stones with an oxalate component, or known proteinuria should discuss creatine with a nephrologist before starting. Creatine itself may be safe in those populations, but the monitoring threshold for acting on a creatinine change is lower.

What About the Alcohol Warning on Addyi?

The FDA added a black-box warning to Addyi's label in 2015, later modified in 2019, requiring that women avoid alcohol within 2 hours before taking flibanserin and for the duration of the night. The combination carries a significant risk of severe hypotension and syncope [2]. This warning has nothing to do with creatine, but it frequently surfaces in patient questions about Addyi interactions. Creatine does not affect blood pressure in the way alcohol does, and no hypotensive interaction with flibanserin has been reported or mechanistically expected for creatine.

Dosing Logistics: Does Timing of Creatine Relative to Addyi Matter?

Flibanserin is taken once at bedtime. Creatine is typically taken with a meal or post-workout, which for most women is during the morning or afternoon. There is no absorption window concern, and no evidence that taking creatine close to bedtime affects flibanserin's Cmax or pharmacodynamic response. Spacing the two by several hours is easy in practice and removes any theoretical question about shared gastrointestinal absorption kinetics.

Practical Daily Schedule

A workable routine might look like this: creatine monohydrate 3 to 5 g mixed into a morning protein shake or yogurt, flibanserin 100 mg tablet taken immediately before sleep. This is an 8- to 14-hour separation that eliminates even remote concerns about timing overlap.

Does Creatine Affect Sexual Function Directly?

A small but growing body of research examines creatine's neurological and hormonal effects. One frequently cited concern is whether creatine supplementation raises dihydrotestosterone (DHT) levels, which could theoretically confound HSDD treatment in some women. A 2009 trial published in Clinical Journal of Sport Medicine (N=20 male rugby players) found a rise in the DHT-to-testosterone ratio after creatine loading [6], but this was a male cohort, used a loading protocol, and the finding has not been replicated in women. No published trial has examined creatine's effect on sexual desire scores in women, and no mechanism connects creatine-related DHT changes to the central serotonergic and dopaminergic pathways that flibanserin targets.

Lean Mass, Energy, and Quality-of-Life Context

Women taking Addyi for HSDD may also have co-occurring fatigue, low mood, or reduced physical capacity, conditions for which creatine has demonstrated benefit. A 2021 meta-analysis in Nutrients (15 trials, N=405 women) found that creatine supplementation produced a mean increase in lean mass of 1.37 kg compared with placebo in resistance-training women [7]. Improved physical energy and body composition can contribute positively to sexual well-being, so creatine may actually complement the goals of HSDD treatment even if it does not directly modify the neurochemical targets of flibanserin.

Guidance From Prescribing Information and Clinical Guidelines

The Addyi prescribing information lists the following categories of interactions requiring attention: CYP3A4 inhibitors (strong and moderate), CYP2C19 inhibitors, CNS depressants, and alcohol [2]. Dietary supplements are not explicitly listed in the label's interaction section. The Natural Medicines database (formerly Natural Standard) classifies the creatine-flibanserin pair as having insufficient evidence to rate a direct interaction, noting only the indirect creatinine monitoring concern described above.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not address creatine specifically, but recommends comprehensive medication and supplement review at initiation of any HSDD therapy [8]. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction similarly recommends disclosure of all supplements at initiation of pharmacological treatment for HSDD [9].

As the Addyi prescribing information states directly: "Patients should be counseled to avoid alcohol during treatment with ADDYI" and "Healthcare providers should assess patients for alcohol use before prescribing ADDYI" [2]. The same principle of full disclosure logically extends to supplements that affect standard monitoring labs.

Special Populations: Considerations Beyond the Average User

Perimenopausal Women

Addyi is approved only for premenopausal women, but some prescribers use it off-label in perimenopausal women. Creatine's benefits for muscle preservation during the menopausal transition are well-documented, and a 2022 review in the Journal of Clinical Endocrinology and Metabolism found that creatine combined with resistance training attenuated perimenopausal muscle and bone loss [10]. The same monitoring framework above applies.

Women With Elevated BMI

Flibanserin's pharmacokinetics are not substantially altered by body weight across the studied range. Creatine's effect on serum creatinine can be more pronounced in women with larger lean muscle mass, because more creatine is stored and degraded. Women who are lean and heavily muscled from resistance training may see the largest creatinine elevations from creatine loading and should therefore prioritize a baseline CMP.

Women on Oral Contraceptives or HRT

Oral contraceptives that contain ethinyl estradiol are moderate CYP3A4 inhibitors and can raise flibanserin plasma concentrations. This is an existing flibanserin interaction already flagged in the label [2]. Creatine does not change this interaction or worsen it. Women on hormonal contraception who also take creatine and Addyi are managing two separate issues: the OC-flibanserin interaction (well-documented, dose-relevant) and the creatine-creatinine monitoring concern (indirect, lab-only).

Summary of Key Points

Creatine and flibanserin (Addyi) do not interact pharmacokinetically or pharmacodynamically. The only meaningful clinical issue is that creatine elevates serum creatinine through increased muscle creatine turnover, which can mislead prescribers conducting routine renal monitoring for Addyi patients. A structured approach, starting with a baseline CMP, using maintenance-dose creatine (3 to 5 g per day) rather than aggressive loading when possible, and rechecking creatinine at 4 to 6 weeks, allows women to use both products safely. Cystatin C measurement provides definitive clarification when creatinine results are ambiguous.

The 2021 meta-analysis in Nutrients showing a mean 1.37 kg lean mass gain in women with creatine supplementation [7] is a reminder that creatine is among the most evidence-supported supplements available, and its benefits for women's physical health are substantial enough to warrant a monitoring plan rather than reflexive avoidance.